Solid Biosciences to Join Chardan’s 7th Annual Summit on Genetic Medicines and Cell Therapy Manufacturing

Solid Biosciences, a life science company focusing on genetic medicines for neuromuscular and cardiac diseases, has announced that it will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. The event will take place on Monday, April 24, 2023, at 2:00 PM ET. Institutional investors interested in meeting with management during the conference may reach out to their Chardan representative.

Solid Biosciences is advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.

Also Read:

The Laser Welding Wires market is a global phenomenon and its current size and growth rate are poised to continue at an impressive 4.2% CAGR from 2023 – 2030

The company aims to be the center of excellence by bringing together expertise in science, technology, disease management, and care. Founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases.

The fireside chat is a part of Chardan’s annual conference, which brings together leaders in genetic medicine and cell therapy manufacturing. Solid Biosciences management will participate in the chat to share their expertise in the field and provide insight into the company’s ongoing research and development efforts.

Also Read:

The report on the Rigid Sterilization Containers market presents a comprehensive analysis of its scope and size, along with the company profiles and market share analysis from 2023 to 2030, projected to grow at a CAGR value of 7.8%.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website. A replay will be available on the Company’s website following the event.

David Carey, an investor contact at Solid Biosciences, can be reached at FINN Partners at 212-867-1768 or [email protected] Tim Palmer, the Associate Director of Corporate Communications at Solid Biosciences, can be reached at 607-760-4223 or [email protected]

Also Read:

The Patient Infotainment System market research report’s foreign opportunities and dynamics analysis explores the market’s size with a CAGR of 10.7% from 2023 – 2030, including analysis on revenue generation, COVID-19 impact, and application.

Solid Biosciences’ participation in the 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit highlights the company’s commitment to advancing the field of genetic medicine and developing innovative therapies for patients suffering from neuromuscular and cardiac diseases. As the company continues to advance its research and development efforts, investors and industry leaders will undoubtedly watch closely.

In Other News Around the World:

The Laser Welding Wires market is a global phenomenon and its current size and growth rate are poised to continue at an impressive 4.2% CAGR from 2023 – 2030

The report on the Rigid Sterilization Containers market presents a comprehensive analysis of its scope and size, along with the company profiles and market share analysis from 2023 to 2030, projected to grow at a CAGR value of 7.8%.

The Patient Infotainment System market research report’s foreign opportunities and dynamics analysis explores the market’s size with a CAGR of 10.7% from 2023 – 2030, including analysis on revenue generation, COVID-19 impact, and application.